Citations

Clear

1446 citation(s) found for "Howard, F".

Outcomes of Lymphovenous Anastomosis for Lower Extremity Lymphedema: A Systematic Review
Verhey, Erik M., Kandi, Lyndsay A. , Lee, Yeonsoo Sara , Morris, Bryn E., Casey, William J., Rebecca, Alanna M. , Marks, Lisa , Howard, Michael A., Teven, Chad M. , Lee, Yeonsoo S, Marks, Lisa A., Sara Lee, Yeonsoo , Marks, Lisa A

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | October 7, 2022 | Volume: 10 | Issue: 10 | Pages: e4529

10.1097/gox.0000000000004529 | PMID 36225843 Get It

Background: Lymphovenous anastomosis (LVA) is a microsurgical treatment for lymphedema of the lower extremity (LEL). This study systematically reviews the most recent data on outcomes of various LVA techniques for LEL in diverse patients. Methods: A comprehensive literature search was conducted in the Ovid MEDLINE, Ovid EMBASE, and Scopus databases to extract articles published through June 2021. Studies reporting data on objective postoperative improvement in lymphedema and/or subjective improvement in quality of life for patients with LEL were included. Extracted data comprised demographics, number of patients and lower limbs, duration of symptoms before LVA, surgical technique, duration of follow-up, and objective and subjective outcomes. Results: A total of 303 articles were identified and evaluated, of which 74 were ultimately deemed eligible for inclusion in this study, representing 6260 patients and 2554 lower limbs. The average patient age ranged from 22.6 to 76.14 years. The duration of lymphedema before LVA ranged from 12 months to 11.4 years. Objective rates of improvement in lymphedema ranged from 23.3% to 100%, with the greatest degree of improvement seen in patients with early-stage LEL. Conclusions: LVA is a safe and effective technique for the treatment of LEL of all stages. Several emerging techniques and variations may lead to improved patient outcomes.
Association of Early Steroid Administration With Outcomes of Children Hospitalized for COVID-19 Without Multisystem Inflammatory Syndrome in Children
Nadiger, Meghana , McGarvey, Jeremy , Harthan, Aaron A. , Lombardo, Mónica, Perkins, Nicholas , Sayed, Imran A., Bhalala, Utpal , Raju, Umamaheswara, Miller, Aaron S., Boman, Karen , Arteaga, Grace M. , Bansal, Vikas , Tekin, Aysun , Kumar, Vishakha K. , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Kovačević, Tanja , Markić, Joško , Ardalic, Tatjana Capitovic , Polić, Branka , Ivić, Ivo, Carev, Dominko , Glavinić, Robert, Vadgaonkar, Girish, Ediga, Rekha, Basety, Shilpa, Dammareddy, Shwetha, Kasumalla, Phani Sreeharsha, Manduva, Janaki, Kolakani, Naresh, Sripathi, Shreeja , Chaitanya, Sheetal, Papani, Sridhar, Kamuram, Mahesh, Mohan, Surapaneni Krishna, Jyothisree, Ekambaram, Petrolwala, Mukur, Ladva, Bharat, Kodate, Akira, Suzuki, Reina , Moriki, Koyo, Hassan-Hanga, Fatimah , Gezawa, Abubakar Shehu, Kabara, Halima M. S., Amole, Taiwo Gboluwaga , Kabir, Halima , Haliru, Dalha Gwarzo, Ibrahim, Abdullahi S., Asghar, Muhammad Sohaib , Syed, Mashaal , Naqvi, Syed Anosh Ali, Yasmin, Farah , Ahmed, Iftekhar , Ishaque, Sidra , Saleem, Ali Faisal , Alarifi, Mohammed I, Macarambon, Jara Mia, Bukhari, Ahmad Abdullah, Albahrani, Hussain A., Aldossary, Kaltham M., Malki, Walid, Kouzoukas, Brenna, Jacobs, Nekaiya, Ganbote, Tejashree, Valentine, Beryl, Sreerama, Pavan, Havalad, Vinod, Barry, Suzanne, Woll, Christopher , Wu, Gregory F. , Carrole, Erin, Burke, Kathryn , Irby, Katherine , Sanders, Ronald C., Hefley, Glenda, Christie, Amy B. , Adiga, Rajani, Campbell, Beth Salvagio , Wilson, Cathleen, Rivers, Patrick , Brinks, Jonathan, Mongoh, Mokenge Ndiva, Gilson, Boris, Danesh, Valerie , Dubrocq, Gueorgui , Davis, Amber, Hammers, Marissa J, McGahey, Ill M, Farris, Amanda C., Priest, Elisa L. , Korsmo, Robyn, Fares, Lorie, Skiles, Kathy, Shor, Susan M, Burns, Kenya, Dowell, Corrie A., Gonzales, Gabriela “ Hope”, Flores, Melody, Newman, Lindsay, Wilk, Debora A., Ettlinger, Jason, Bomar, Jaccallene, Darji, Himani, Arroliga, Alejandro C. , Khandhar, Paras B., Kring, Elizabeth, Anderson, Edwin L., Nagy, Rosemary, Inja, Ravali R., Nawathe, Pooja , Tsing, Jennifer, Carr, Karen, Chaudhary, Anila , Guglielmino, Kathleen, Strom, Larisa, Chiotos, Kathleen, Lee, Giyoung , Burnett, Ryan H., Sydney, Guy I. , Traynor, Danielle M., Ahmed, Farzin, Deonarine, Christopher, Jones, Ashley, Shaikh, Mohammad-Ali , Preston, David A. , Chin, Jeanette, Milligan, Patrick S., Koglin, Joy M., Gibson, Regina, Johnson, Lana, Preston, Felicia, Scott, Crimson, Nungester, Bethany, Menter, Sarah, Wasilewski, A., Kaul, Viren , Austin, Praise, Rogner, Jaimie, Russo, Anthony J. , Ontai, Sidney , Contreras, Brian, Obinwanko, Uzoma, Amamasi, Nneka, Sharafi, Amir, Kaufman, Margit, Lobel, G, Gandhi, Nisha, AbdelAty, Amr M. , Shaji, Elizabeth, Lim, Kiana, Marte, Juan M., Sosa, Dani Ashley, Roth, Prerana , Litwin, Alain H. , Pariyadath, Anand, Moschella, Phillip , Llano, Trayson, Salas, Alan, Daube, Ariel , Korn, Michelle, Rajagopalan, Logi, Santos, Laura Jurema dos , Crandall, Christine , Stojanovski, Sasko, Michienzi, Kelly, Amer, Marwa , Dahhan, Talal, Kseibi, Eiad, Butt, Abid, Khurshid, Syed Moazzum, Rabee, Muath, Abujazar, Mohammed, Alghunaim, Razan, Abualkhair, Maal, AlFirm, Abeer Turki, Oulds, Franscene, Nandavar, Akshay, Wen, Andy , DaCar, Allie, Reilkoff, Ronald A., Eichen, Sarah, Goertzen, Lexie, Rajala, Scott, Feussom, Ghislaine, Domecq, Juan Pablo , Sharma, Mayank , Qamar, Shahraz , Morales, Diana J. Valencia , Khan, Syed Anjum , Jain, Nitesh , Wang, Christine, Kotekal, Dhatri, Sendi, Prithvi , Aulakh, Bhagat , Bandy, Jennifer A., Kreps, Lisa M., Bollinger, Dawn R., Nadiger, Meghana, Schauf, Victoria, Rich, Deana, Anderson, Harry L., Rajkumar, Dixy, Abunayla, Ali, Heiter, Jerrilyn, Zaren, Howard A. , Smith, Stephanie J., Lewis, Grant C., Seames, Lauren, Farlow, Cheryl, Miller, Judy, Broadstreet, Gloria, Terrill, Cindy, Montgomery, Brock, Reyes, Sydney A, Reyes, Summer M, Plattner, Alex, Martinez, Anthony , Allison, Micheal, Mittal, Aniket, Ruíz, Rafael Azuar , Skaanland, Aleta, Amzuta, Ioana, Shah, Amish , Modi, Ritu, Al-Khalisy, Hassan, Masuta, Pardeep , Schafer, Melissa , Wratney, Angela, Jones, Tracy L., Ayers, Shonda C., Harrell, Amy B., Brown, Brent R., Malone, Kassidy, Sinko, Lauren A, Hrarrell, Amy B, Settle, Lisa, Sears, Taylor J., Kuehne, Joshua, Garcia, Melinda, Beebe, Morgan, Herrera, Heather , Belden, Katherine A. , Baram, Michael , Weber, Devin , DePaola, Rosalie, Xia, Yuwei , Carter, Hudson, Tolley, A. E., Ferranti, Mary, House, Scott, Aldana, Isabella, Stulce, Casey , Chong, Grace , Ghavam, Ahmeneh , Baslanti, Tezcan Ozrazgat, Omalay, George, Hashemighouchani, Haleh , Cupka, Julie S , Hubbard, Janice, Nazir, Usman, Rampon, Garrett , Riggle, Jake, Dismang, Nathan, Sullivan, Janice, Morris, Sarah, Nason, Jennifer, Rahman, Rania Abdul, Mulrow, Mary, Gál, Tamás, Mahashabde, Manasi, Vagonis, Alexandra , Uber, Rebecca, Mahmud, Haseeb , Leightle, Stefan, Zhang, Zoe, Vissichelli, Nicole C. , O'Meara, A M Iqbal, Rocawich, Katie, Harris, Lynnette , Cusson, Bruce, Reeves, Brandon, Fanelli, Jessica, Disher, Nataya, Samant, Anusha, DeGroot, Chritian, Youshock, Evan, Ligon, R. Miller, McCartney, Katherine, Garcia, Julio, Iloabachie, Chidi, Flores, Kelsey, VanEenenaam, David P., Sands, Lauren , Sweatt, Nia, Fowler, Jacob , Fram, Madeline, Howard, Easton, Johnson, Kathleen N. , Udoh, Imoh, Nosow, Lillian, Howard, Lucy Winesett, Pham, Quan Duc Minh, Irfanullah, Aman, Ong, Tiffany, Enwezor, Chukwunyelu Henry, Dabagian, Hannah, Bansal, Vikas , Asghar, Muhammad S , Tekin, Aysun , Tripathi, Sandeep , Lombardo, Monica, Gharpure, Varsha , Chiotos, Kathleen , Bjornstad, Erica C. , Dapul, Heda , Montgomery, Vicki , Deo, Neha , Gajic, Ognjen , Kashyap, Rahul , Walkey, Allan J. , Group, Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): COVID-19 Registry Investigator, Itagaki, Yuki , Galadanci, Hadiza , Kabara, Halima Salisu, Syed, Mashaal, Almazyad, Mohammed , Asfina, Kazi Nur , Cooper, Paul R. , Burke, Kathryn, Mohammed, Mustafa, Ashley, Dennis W. , Mosier, Jarrod , Lutrick, Karen , Dubrocq, Gueorgui , Nagy, Rosemary, Inja, Ravali R., Pedraza, Isabel , Carr, Karen, Gist, Katja M. , Chiotos, Kathleen, Blatz, Allison M. , Cheruku, Sreekanth , Preston, David, Gupta, Sandeep , Abdelaty, Amr, Rennert, Lior , Ramírez, Michelle , Verma, Sourabh , Stojanovski, Sasko D., Johnson, Kristin, Bawazeer, Mohammed Abdullah , Gupta, Manoj , Heneghan, Julia A. , Tang, Ben, Lal, Amos , O’Horo, John C. , Singh, Romil , Koritala, Thoyaja , Tarabichi, Yasir , Perzynski, Adam T. , Wang, Christine, Totapally, Balagangadhar , Nadiger, Meghana, Wall, Chris, Menon, Shina , McGuire, John K. , Anderson, Harry L., Miller, Judy, Lin, John C. H. , Montgomery, Brock, Ruiz, Rafael, Ross, Robert, Gupta, Neha , Brown, Brent , Tolley, Aaron, Tofil, Nancy M. , Mayampurath, Anoop , Bihorac, Azra , Ruppert, Matthew M. , McGonagill, Patrick W. , Galet, Colette , Wang, David , Allan, Lauren , Badheka, Aditya V. , Chegondi, Madhuradhar , Sullivan, Janice, Nason, Jennifer, Akhter, Murtaza , Kashiouris, Markos , Gal, Tamas, Karam, Oliver , Carvalho, Heloisa De, Khanna, Ashish K. , Garcia, Julio, Robinson, Samuel, Enwezor, Chukwunyelu Henry , Mendoza, Rafael

Mayo Clinic

JAMA Pediatrics | October 3, 2022 | Volume: 176 | Issue: 12 | Pages: 1208

10.1001/jamapediatrics.2022.3611 | PMID 36190706 Get It

ImportanceThere is limited evidence for therapeutic options for pediatric COVID-19 outside of multisystem inflammatory syndrome in children (MIS-C).ObjectiveTo determine whether the use of steroids within 2 days of admission for non–MIS-C COVID-19 in children is associated with hospital length of stay (LOS). The secondary objective was to determine their association with intensive care unit (ICU) LOS, inflammation, and fever defervescence.Design, Setting, and ParticipantsThis cohort study analyzed data retrospectively for children (<18 years) who required hospitalization for non–MIS-C COVID-19. Data from March 2020 through September 2021 were provided by 58 hospitals in 7 countries who participate in the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS) COVID-19 registry.ExposureAdministration of steroids within 2 days of admission.Main Outcomes and MeasuresLength of stay in the hospital and ICU. Adjustment for confounders was done by mixed linear regression and propensity score matching.ResultsA total of 1163 patients met inclusion criteria and had a median (IQR) age of 7 years (0.9-14.3). Almost half of all patients (601/1163, 51.7%) were male, 33.8% (392/1163) were non-Hispanic White, and 27.9% (324/1163) were Hispanic. Of the study population, 184 patients (15.8%) received steroids within 2 days of admission, and 979 (84.2%) did not receive steroids within the first 2 days. Among 1163 patients, 658 (56.5%) required respiratory support during hospitalization. Overall, patients in the steroids group were older and had greater severity of illness, and a larger proportion required respiratory and vasoactive support. On multivariable linear regression, after controlling for treatment with remdesivir within 2 days, country, race and ethnicity, obesity and comorbidity, number of abnormal inflammatory mediators, age, bacterial or viral coinfection, and disease severity according to ICU admission within first 2 days or World Health Organization ordinal scale of 4 or higher on admission, with a random intercept for the site, early steroid treatment was not significantly associated with hospital LOS (exponentiated coefficient, 0.94; 95% CI, 0.81-1.09; P = .42). Separate analyses for patients with an LOS of 2 days or longer (n = 729), those receiving respiratory support at admission (n = 286), and propensity score–matched patients also showed no significant association between steroids and LOS. Early steroid treatment was not associated with ICU LOS, fever defervescence by day 3, or normalization of inflammatory mediators.Conclusions and RelevanceSteroid treatment within 2 days of hospital admission in a heterogeneous cohort of pediatric patients hospitalized for COVID-19 without MIS-C did not have a statistically significant association with hospital LOS.
Post-protocol therapies in first-line immunotherapy trials in non–small cell lung cancer (NSCLC).
Leventakos, Konstantinos , Adjei, Alex A. , West, Howard , Desai, Aakash , Mansfield, Aaron S. , Kommalapati, Anuhya

Mayo Clinic

Journal of Clinical Oncology | September 30, 2022 | Volume: 40 | Issue: 28_suppl | Pages: 125-125

10.1200/jco.2022.40.28_suppl.125 Get It

125 Background: The advent of immunotherapy (IO) has led to significant improvement in outcomes for patients (pts) with advanced non-small cell lung cancer (adv NSCLC). The rate of crossovers and receipt of post-protocol IO in pivotal trials leading to FDA approvals of IO in NSCLC has not been systematically evaluated. Here, we evaluate crossover rates and post protocol therapies for pts with adv NSCLC across multiple first-line (1L) IO monotherapy and chemotherapy/IO (chemo/IO) combination trials. Methods: We utilized the publicly available data from pivotal clinical trials leading to approvals of IO or chemo/IO regimens in 1L treatment of adv NSCLC. We extracted data on outcomes, rate of crossover from control arm to IO, proportion of pts in control arm receiving IO and the start dates of these clinical trials. The primary outcomes were the rates of crossover and the proportion of patients in control arms who received post-control IO. Results: The study included 4 trials with IO monotherapy and 12 trials with chemo/IO combinations in 1L adv NSCLC. The primary endpoints for these trials were PFS (25%), OS (19%), and both PFS and OS (56%). The crossover rate from control arm to experimental arm (with IO) ranged from 0-74% in IO monotherapy trials and 0-49% in chemo/IO trials. Two IO monotherapy trials and five chemo/IO trials did not allow crossover; among them, 3 trials had a PFS/OS co-primary endpoint, while others had OS as primary endpoint. Ten of 16 trials provided explicit information on use of subsequent post-protocol therapies in their publications. Among the two IO monotherapy trials which did not allow crossover, post-protocol IO was administered in only 20-30% of patients. Among the six chemo/IO trials with information on post-protocol therapies, 30%-59% patients on the control arm subsequently received some form of IO on progression. Nine of 12 trials started accrual after 10/2015, when nivolumab was approved in the United States as second-line (2L) therapy for adv NSCLC regardless of tumor PD-L1 expression. Conclusions: Despite the highly significant OS benefit from 2L IO, which was the standard of care (SOC) in the United States, the rates of crossover and post-protocol IO administration was distressingly low in 1L IO monotherapy and chemo/IO trials for 1L adv NSCLC. This low rate of 2L treatment with IO may have been due to limited global availability prior to widespread regulatory approval during the conduct of these trials. There is an increased need for consistency in reporting of crossover treatment and post-protocol treatments to allow adequate assessment of the true 1L benefit with IO. Control arms in pivotal trials require scrutiny to ensure confirmation with SOC to provide access to optimal treatments for patients and prevent magnification of observed benefits in experimental arms. The difficulty lies in the global conduct of large randomized clinical trials with differing regulatory approvals.
Supporting International Medical Graduates in Rheumatology: A Call to Action
Fernandez‐Ruiz, Ruth , Duarte‐García, Alí , Rolle, Noelle A. , Sattui, Sebastian E. , Saygın, Didem , Dowell, Sharon , Alexander, Swetha Ann , Kumar, Bharat , Danila, Maria I. , Singh, Namrata , Duarte-García, Alí , Sattui, Sebastian E

Mayo Clinic

Arthritis & Rheumatology | September 30, 2022 | Volume: 75 | Issue: 2 | Pages: 145-148

10.1002/art.42373 | PMID 36177492 Get It

Recommendations From the International Consensus Conference on Anemia Management in Surgical Patients (ICCAMS)
Shander, Aryeh , Corwin, Howard L., Meier, Jens , Bisbe, Elvira , Erhard, J., Faraoni, David , Farmer, Shannon L. , Hall, Tiffany , Hardy, Jean‐François, Hofmann, Axel , Lee, Cheuk‐Kwong, Leung, Tsin Wah, Ozawa, Sherri , Sathar, Jameela , Torres, Rosalio, Múñoz, Manuel , Auerbach, Michael , Blitz, Jeanna D. , Frank, Steven M. , Girelli, Domenico , Lee, Cheuk Kwong , Spahn, Donat R. , Warner, Matthew A.

Mayo Clinic

Annals of Surgery | September 22, 2022 | Volume: 277 | Issue: 4 | Pages: 581-590

10.1097/sla.0000000000005721 | PMID 36134567 Get It

Background: Perioperative anemia has been associated with increased risk of red blood cell transfusion and increased morbidity and mortality after surgery. The optimal approach to the diagnosis and management of perioperative anemia is not fully established. Objective: To develop consensus recommendations for anemia management in surgical patients. Methods: An international expert panel reviewed the current evidence and developed recommendations using modified RAND Delphi methodology. Results: The panel recommends that all patients except those undergoing minor procedures be screened for anemia before surgery. Appropriate therapy for anemia should be guided by an accurate diagnosis of the etiology. The need to proceed with surgery in some patients with anemia is expected to persist. However, early identification and effective treatment of anemia has the potential to reduce the risks associated with surgery and improve clinical outcomes. As with preoperative anemia, postoperative anemia should be treated in the perioperative period. Conclusions: Early identification and effective treatment of anemia has the potential to improve clinical outcomes in surgical patients.
Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis
Oddis, Chester V. , Rockette, Howard E., Zhu, Lei , Koontz, Diane, Lacomis, David , Venturupalli, Swamy, Moghadam‐Kia, Siamak , Ascherman, Dana P. , Dimachkie, Mazen M. , Ernste, Floranne C. , Gazeley, David , Marder, Galina , Ascherman, Dana P. , Oddis, Chester V , Dimachkie, Mazen M , Crofford, Leslie J. , Aggarwal, Rohit

Mayo Clinic

ACR Open Rheumatology | September 21, 2022 | Volume: 4 | Issue: 11 | Pages: 983-990

10.1002/acr2.11493 | PMID 36128663 Get It

Objective To assess the efficacy and tolerability of tocilizumab in a multicenter, randomized, double‐blind, placebo‐controlled trial in refractory adult patients with dermatomyositis (DM) and polymyositis (PM). Methods Thirty‐six subjects with probable or definite DM/PM were enrolled in a 6‐month phase 2B clinical trial and randomized 1:1 to receive tocilizumab (8 mg/kg intravenously) or placebo every 4 weeks for 24 weeks. Eligible subjects had either a DM rash, a myositis‐associated autoantibody or an adjudicated PM diagnosis. Active disease was defined by at least three of six abnormal core set measures (CSMs), including a manual muscle testing (MMT)‐8 score of less than 136/150. If the MMT‐8 score was greater than 136, then a cutaneous score of 3 or more (10 cm visual analogue scale) was required along with three additional abnormal CSMs indicating disease activity. The primary endpoint compared the Total Improvement Score (TIS) between both arms from week 4 to 24. Secondary outcomes included time to meeting minimal TIS improvement, changes in CSMs, time to worsening, steroid‐sparing effect, proportion of subjects meeting more stringent improvement criteria, and safety outcomes. Results There was no significant difference ( P = 0.86) in the TIS over 24 weeks between tocilizumab and placebo arms. The secondary endpoints of time to improvement (minimal, moderate, or major), time to worsening, CSM changes, safety outcomes, and steroid‐sparing effect were also not significantly different between arms. Conclusion Tocilizumab was safe and well tolerated but did not meet the primary or secondary efficacy outcomes in refractory DM and PM in this 24‐week phase 2B study.
Incobotulinum toxin A: A shelf‐stable, low‐molecular‐weight formulation
Grunebaum, Lisa D., Howard, Brittany E. , Eells, Annica C.

Mayo Clinic

Dermatological Reviews | September 14, 2022 | Volume: 3 | Issue: 4 | Pages: 211-217

10.1002/der2.157 Get It

AbstractSince its development in 2005, incobotulinum toxin A (INCO) has become one of the most widely used neurotoxins worldwide for aesthetic and therapeutic indications. It was initially designed as a formulation free of complex proteins for reduced immunogenicity with an equal action and strength profile to the original and widespread onabotulinum toxin A (ONA). Multiple trials have demonstrated equivalent efficacy. Several studies have suggested a slight decrease in the time of visible treatment onset with INCO and a subsequent lack of difference in duration of effects when compared with ONA. Particularly appreciable with therapeutic doses, utilization of INCO led to significant cost savings over ONA or abobotulinum toxin A. Karschney et al. found that for the treatment of cervical dystonia and chronic migraine the cost to patients was reduced by 32.2% compared to ONA. Additionally, the ONA formulation allows for long‐term storage at room temperature along with an increased stability time once reconstituted. Limitations of INCO include a similar side effect profile to other neurotoxin formulations, more likely at therapeutic dosing. Indications approved by the Federal Drug Administration in the United States and other regulatory agencies are currently more limited than those of ONA, though this may be in direct relation to the length of time on the market. INCO has overall been demonstrated to be a safe, efficacious alternative to other common neurotoxin formulations.
Plastic Surgery’s Obligation to the Transgender Community
Jarvis, Nicholas R. , Jordan, Sumanas W. , Howard, Michael A., Teven, Chad M.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 14, 2022 | Volume: 10 | Issue: 9 | Pages: e4502

10.1097/gox.0000000000004502 | PMID 36119380 Get It

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
DiIorio, Michael , Kennedy, Kevin , Putman, Michael , Sirotich, Emily , Sattui, Sebastian E. , Foster, Gary , Harrison, Carly , Larché, Maggie , Levine, Mitchell , Moni, Tarin T , Thabane, Lehana , Bhana, Suleman , Costello, Wendy, Grainger, Rebecca , Machado, Pedro , Sufka, Paul , Wallace, Zachary S. , Gore‐Massy, Monique , Kodhek, More A, Lalonde, Nadine, Tomasella, Laura-Ann, Wallace, John, Akpabio, Akpabio , Alpizar-Rodriguez, D. , Berenbaum, Françis , Buliņa, Inita , Chock, Eugenia Yupei , Duff, Eimear , Hsieh, Evelyn , Kibbi, Lina El, Liew, David , Lo, Chieh , Nudel, Michal, Singh, Aman Dev , Hausmann, Jonathan S. , Sparks, Jeffrey A. , Putman, Michael S , Sirotich, Emily , Sattui, Sebastian E , Machado, Pedro M , Robinson, Philip C , Akpabio, Akpabio , Alpízar-Rodríguez, Deshiré , Berenbaum, Francis , Chock, Eugenia Yupei , Liew, David Fl , Singh, Jasvinder A , Ugarte-Gil, Manuel F , Hausmann, Jonathan S , Simard, Julia F , Sparks, Jeffrey A , Grainger, Rebecca , Hsieh, Evelyn , Thabane, Lehana , Kennedy, Kevin , Liew, Jean W. , Robinson, Philip C. , Yazdany, Jinoos , Howard, Richard A, Wallace, John, Beesley, Richard P. , Conway, Richard , Duarte‐García, Alí , Gheita, Tamer A. , Graef, Elizabeth R. , Singh, Jasvinder A. , Singh, Namrata , Ugarte‐Gil, Manuel F.

Mayo Clinic

RMD Open | September 14, 2022 | Volume: 8 | Issue: 2 | Pages: e002587

10.1136/rmdopen-2022-002587 | PMID 36104117 Get It

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs). Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression. Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81). Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.
Surgical treatment of brain arteriovenous malformations: clinical outcomes of patients included in the registry of a pragmatic randomized trial
Darsaut, Tim E. , Magro, Elsa, Bojanowski, Michel W., Chaalala, Chiraz , Nico, Lorena , Bacchus, Emma, Klink, Ruby , Sabatier, Jean-François, Januel, Anne-Christine , Pélissou-Guyotat, I., Roche, Pièrre-Hugues , Brunel, Hervé, Proust, F. , Cornu, Philippe, Gaberel, Thomas , Barbier, Charlotte , Corre, Marine Le, Costalat, Vincent , Jecko, Vincent , Barreau, Xavier , Gauvrit, Jean‐Yves , Derrey, Stéphane , Papagiannaki, Chrysanthi , Abdalkader, Mohamad , Viard, Geraldine, Raymond, Jean , _, _, _, _, Chow, Michael M. C., Findlay, J. Max , Lesiuk, Howard , Drake, Brian , Santos, Marlene dos, Seizeur, Romuald, Pradier, Olivier, Ognard, Julien, Aouni, Mourad Cheddad El , Boursier, Romain, Thillays, F. , Roualdes, Vincent , Calvière, Lionel , Gauvrit, J.Y., Lecouillard, Isabelle, Nouhaud, Elodie, Raoult, Hélène , Eugene, François, Paya, Christophe, Ronzière, Thomas , Trystram, D. , Naggara, Olivier, Emery, Évelyne , Pellisou-Guyotat, Isabelle, Guyotat, Jacques, Berhouma, Monsef, Riva, Roberto, Biondi, Alessandra , Thines, L. , Bougaci, Nassim , Bracard, Serge, Anxionnat, René , Bernier‐Chastagner, Valérie , Civit, Thierry, Penchet, Guillaume, Gimbert, Edouard, Marnat, Gaulthier, Huchet, Aymeri, Herbreteau, Denis , Bibi, Richard, Ifergan, Héloïse , Janot, Kévin, Peyrière, Hadrien, Kaya, Jean-Marc, Touta, Adamou, Troude, Lucas, Boissonneau, Sébastien , Boch, Anne‐Laure , Clarençon, Frédéric , Nouet, Aurélien , Premat, Kévin, Gascou, Gregory, Lefevre, Pierre-Henri, Riquelme, Carlos , Cébula, H. , Ollivier, Irène , Pop, Raoul, Spatola, Giorgio, Chalumeau, Vanessa, Ikka, Léon , Ozanne, Augustin , Caroff, Jildaz, Chabert, Emmanuel , Rouchaud, Aymeric, Caire, François, Ricolfi, F. , Cao, Catherine, Mourier, Klaus-Luc, Thouant, Pierre, Farah, Walid, Carlson, Andrew P. , Silva, Luciana Alves Oliveira, Froio, Nayara de Lima, Mont’Alverne, Francisco J. A., Martins, Jose Luri, Mendes, George Nilton Nunes , Miranda, Rodrigo Rivera, Rouchaud, Aymeric , Rivera, Rodrigo , Ognard, Julien , Shotar, Eimad , Rouchaud, Aymeric , Ognard, Julien , Bojanowski, Michel W. , Iancu, Daniela , Weill, Alain , Roy, Daniel C. , Cognard, Christophe , Eker, Omer , Graillon, Thomas , Beaujeux, Rémy , Aldéa, Sorin , Piotin, Michel , Shotar, Eimad , Corre, Marine Le, Morandi, Xavier , Nguyen, Thanh N. , Tawk, Rabih G. , Huynh, Thien , Gévry, Guylaine , Gentric, Jean‐Christophe , _, _, _, _, Rempel, Jeremy L , O'Kelly, Cian J , Fahed, Robert , Santos, Marlene dos, Nonent, Michel , Timsit, Serge , Desal, Hubert , Blanc, Raphaël , Eugene, François, Bras, Anthony Le , Ferré, Jean‐Christophe , Paya, Christophe, Rodriguez-Régent, Christine , Kerleroux, Basile , Touzé, Emmanuel , Dumot, Chloé , Charbonnier, Guillaume , Gory, Benjamin , Boulouis, Grégoire , Velut, Stéphane , Bibi, Richard , Troude, Lucas , Sourour, Nader Antoine , Lenck, Stéphanie , Premat, Kévin , Corre, Marine Le, Bonafé, Alain , Dargazanli, Cyril , Gascou, Grégory , Lefèvre, Pierre-Henri , Pop, Raoul , Spelle, Laurent , Chalumeau, Vanessa , Gallas, Sophie , Mihalea, Cristian , Mounayer, Charbel , Thouant, Pierre , Silva, Gisele Sampaio , Montalverne, Francisco Jose

Mayo Clinic

Journal of Neurosurgery | September 9, 2022 | Volume: 138 | Issue: 4 | Pages: 891-899

10.3171/2022.7.jns22813 | PMID 36087316 Get It

OBJECTIVE The Treatment of Brain Arteriovenous Malformations Study (TOBAS) is a pragmatic study that includes 2 randomized trials and registries of treated or conservatively managed patients. The authors report the results of the surgical registry. METHODS TOBAS patients are managed according to an algorithm that combines clinical judgment and randomized allocation. For patients considered for curative treatment, clinicians selected from surgery, endovascular therapy, or radiation therapy as the primary curative method, and whether observation was a reasonable alternative. When surgery was selected and observation was deemed unreasonable, the patient was not included in the randomized controlled trial but placed in the surgical registry. The primary outcome of the trial was mRS score > 2 at 10 years (at last follow-up for the current report). Secondary outcomes include angiographic results, perioperative serious adverse events, and permanent treatment-related complications leading to mRS score > 2. RESULTS From June 2014 to May 2021, 1010 patients were recruited at 30 TOBAS centers. Surgery was selected for 229/512 patients (44%) considered for curative treatment; 77 (34%) were included in the surgery versus observation randomized trial and 152 (66%) were placed in the surgical registry. Surgical registry patients had 124/152 (82%) ruptured and 28/152 (18%) unruptured arteriovenous malformations (AVMs), with the majority categorized as low-grade Spetzler-Martin grade I–II AVM (118/152 [78%]). Thirteen patients were excluded, leaving 139 patients for analysis. Embolization was performed prior to surgery in 78/139 (56%) patients. Surgical angiographic cure was obtained in 123/139 all-grade (89%, 95% CI 82%–93%) and 105/110 low-grade (95%, 95% CI 90%–98%) AVM patients. At the mean follow-up of 18.1 months, 16 patients (12%, 95% CI 7%–18%) had reached the primary safety outcome of mRS score > 2, including 11/16 who had a baseline mRS score ≥ 3 due to previous AVM rupture. Serious adverse events occurred in 29 patients (21%, 95% CI 15%–28%). Permanent treatment-related complications leading to mRS score > 2 occurred in 6/139 patients (4%, 95% CI 2%–9%), 5 (83%) of whom had complications due to preoperative embolization. CONCLUSIONS The surgical treatment of brain AVMs in the TOBAS registry was curative in 88% of patients. The participation of more patients, surgeons, and centers in randomized trials is needed to definitively establish the role of surgery in the treatment of unruptured brain AVMs. Clinical trial registration no.: NCT02098252 (ClinicalTrials.gov)